UY30254A1 - Tratamientos para la alergia ocular - Google Patents

Tratamientos para la alergia ocular

Info

Publication number
UY30254A1
UY30254A1 UY30254A UY30254A UY30254A1 UY 30254 A1 UY30254 A1 UY 30254A1 UY 30254 A UY30254 A UY 30254A UY 30254 A UY30254 A UY 30254A UY 30254 A1 UY30254 A1 UY 30254A1
Authority
UY
Uruguay
Prior art keywords
treatments
eye allergy
allergy
eye
alcaftadine
Prior art date
Application number
UY30254A
Other languages
English (en)
Inventor
Anton Megens
Frans Janssens
Avner Ingerman
Jagdish Parasrampuria
Original Assignee
Vistakon Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vistakon Pharmaceutical Llc filed Critical Vistakon Pharmaceutical Llc
Publication of UY30254A1 publication Critical patent/UY30254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones, kits y métodos para el tratamiento o la prevención de alergias e inflamación oculares y de los síntomas de las mismas que comprende alcaftadina o una sal farmacéuticamente aceptable de la misma.
UY30254A 2006-03-31 2007-04-02 Tratamientos para la alergia ocular UY30254A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78818506P 2006-03-31 2006-03-31
US68801607A 2007-03-19 2007-03-19

Publications (1)

Publication Number Publication Date
UY30254A1 true UY30254A1 (es) 2007-08-31

Family

ID=38468943

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30254A UY30254A1 (es) 2006-03-31 2007-04-02 Tratamientos para la alergia ocular

Country Status (30)

Country Link
US (7) US8664215B2 (es)
EP (2) EP2004196B1 (es)
JP (3) JP5292277B2 (es)
KR (1) KR101321731B1 (es)
CN (1) CN102895234A (es)
AR (1) AR060278A1 (es)
AU (1) AU2007234957B2 (es)
BR (1) BRPI0710085B8 (es)
CA (1) CA2648115C (es)
CL (1) CL2007000916A1 (es)
CR (1) CR10414A (es)
DK (2) DK2004196T3 (es)
EA (1) EA016221B1 (es)
EC (1) ECSP088786A (es)
ES (2) ES2752823T3 (es)
HK (1) HK1131331A1 (es)
IL (1) IL194473A (es)
JO (1) JO3358B1 (es)
MX (1) MX2008012657A (es)
MY (1) MY153669A (es)
NI (1) NI200800261A (es)
NO (1) NO341147B1 (es)
NZ (1) NZ571690A (es)
PE (1) PE20080053A1 (es)
PL (2) PL3150209T3 (es)
SG (1) SG170044A1 (es)
TW (2) TWI578990B (es)
UY (1) UY30254A1 (es)
WO (1) WO2007117971A2 (es)
ZA (1) ZA200809327B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004196B1 (en) 2006-03-31 2016-06-29 Vistakon Pharmaceuticals, LLC Ocular allergy treatments
JP2009535342A (ja) 2006-04-26 2009-10-01 アーシエックス， インコーポレイテッド 眼瞼腫脹の予防および処置のための組成物
BRPI0819105A2 (pt) * 2007-11-08 2019-09-24 Aciex Therapeutics Inc composição para o tratamento e prevenção de edema de pálpebra
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
CA2755679C (en) 2009-03-17 2017-09-12 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014080259A1 (en) * 2012-11-21 2014-05-30 Enaltec Labs Pvt. Ltd. Novel polymorphic forms of alcaftadine
US9255105B2 (en) * 2012-12-06 2016-02-09 Enaltec Labs Private Limited Process of preparing alcaftadine
CN109862851A (zh) 2016-08-12 2019-06-07 蚕丝科技有限公司 用于治疗炎症的丝衍生蛋白质
WO2019022225A1 (ja) * 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
JPWO2019026992A1 (ja) * 2017-08-03 2020-06-18 参天製薬株式会社 クロルヘキシジンを含有する医薬組成物
CA3088740A1 (en) * 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
CA3181959A1 (en) 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
WO2022208146A1 (en) 2021-04-01 2022-10-06 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
WO2024010039A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148903A (en) 1977-07-28 1979-04-10 Merck & Co., Inc. Antipsychotic, antiserotonin and antihistaminic pyrrolo[2,1-b][3]benzazepines
DE3134672A1 (de) * 1981-09-02 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Heterocyclische verbindungen, ihre herstellung und verwendung
GB8900380D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
CA2093797C (en) 1990-10-10 1998-09-22 Richard J. Friary Substituted imidazobenzazepines and imidazopyridoazepines
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US20060100408A1 (en) * 2002-03-11 2006-05-11 Powell P M Method for forming contact lenses comprising therapeutic agents
US20070077302A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20070077303A1 (en) 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
KR20150017002A (ko) * 2006-03-17 2015-02-13 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 눈용 조성물
EP2004196B1 (en) 2006-03-31 2016-06-29 Vistakon Pharmaceuticals, LLC Ocular allergy treatments

Also Published As

Publication number Publication date
NO341147B1 (no) 2017-09-04
ECSP088786A (es) 2009-01-30
JO3358B1 (ar) 2019-03-13
CA2648115A1 (en) 2007-10-18
US20230181594A1 (en) 2023-06-15
EP2004196B1 (en) 2016-06-29
CA2648115C (en) 2015-03-24
JP2015131820A (ja) 2015-07-23
US20120094978A1 (en) 2012-04-19
MX2008012657A (es) 2009-02-19
DK2004196T3 (en) 2016-09-05
KR20080110881A (ko) 2008-12-19
AU2007234957A1 (en) 2007-10-18
NI200800261A (es) 2012-10-30
ES2594655T3 (es) 2016-12-21
JP2013144703A (ja) 2013-07-25
HK1131331A1 (en) 2010-01-22
IL194473A0 (en) 2009-08-03
EP2004196A2 (en) 2008-12-24
BRPI0710085B8 (pt) 2021-05-25
IL194473A (en) 2016-04-21
JP5292277B2 (ja) 2013-09-18
US20170065605A1 (en) 2017-03-09
TWI450721B (zh) 2014-09-01
BRPI0710085B1 (pt) 2019-12-17
TWI578990B (zh) 2017-04-21
NO20084593L (no) 2008-10-29
US20080051385A1 (en) 2008-02-28
DK3150209T3 (da) 2019-10-28
MY153669A (en) 2015-03-13
PL3150209T3 (pl) 2020-03-31
KR101321731B1 (ko) 2013-10-30
WO2007117971A3 (en) 2007-12-27
ES2752823T3 (es) 2020-04-06
CN102895234A (zh) 2013-01-30
EA016221B1 (ru) 2012-03-30
US20140107102A1 (en) 2014-04-17
US8664215B2 (en) 2014-03-04
US20240058355A1 (en) 2024-02-22
TW201446249A (zh) 2014-12-16
JP2009533333A (ja) 2009-09-17
US20210030762A1 (en) 2021-02-04
EP3150209B1 (en) 2019-07-24
US10617695B2 (en) 2020-04-14
PL2004196T3 (pl) 2017-01-31
AR060278A1 (es) 2008-06-04
ZA200809327B (en) 2009-12-30
CL2007000916A1 (es) 2008-01-25
EA200870396A1 (ru) 2009-04-28
BRPI0710085A2 (pt) 2011-08-23
CR10414A (es) 2009-02-23
NZ571690A (en) 2011-09-30
AU2007234957B2 (en) 2012-12-13
PE20080053A1 (es) 2008-03-10
WO2007117971A2 (en) 2007-10-18
EP3150209A1 (en) 2017-04-05
JP6039716B2 (ja) 2016-12-07
SG170044A1 (en) 2011-04-29
TW200815016A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
UY30254A1 (es) Tratamientos para la alergia ocular
CR10347A (es) Anticuerpos contra el peptidob-amiloide
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
CL2012001583A1 (es) Preparación oftálmica que comprende: a) povidona yodada, b) un agente refrescante y c) uno o más entre alcanfor, borneol, lubricante, emoliente, antiinflamatorio esteroidal y antinflamatorio no esteroidal; y su uso para el tratamiento y/o profilaxis de un trastorno ocular o una infección.
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
EA200901211A1 (ru) Антигены белка с5 и их применение
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
CR10226A (es) Combinaciones del inhibidor de ang2 y vegf
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
CR9580A (es) Inhibidores de la actividad akt
GT200500360A (es) Compuestos organicos
AR059928A1 (es) Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
ES2689971T3 (es) Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina
UY30986A1 (es) Derivados fluorinados de deferiprona
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
UY33153A (es) Formulación tópica oftálmica de péptidos
CL2012000801A1 (es) Composición farmacéutica en solución acuosa que comprende olopatadina y un compuesto derivado de quinolina sustituida, inhibidor de pde4; y uso para el tratamiento de una condición alérgica o inflamatoria del ojo, la nariz o la piel.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20170512